✦ LIBER ✦

Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors

✍ Scribed by Hiroyuki Kobayashi; S. Gail Eckhardt; Jennifer A. Lockridge; Mace L. Rothenberg; Alan B. Sandler; Cindy L. O’Bryant; Wendy Cooper; Scott N. Holden; Roger D. Aitchison; Nassim Usman; Maurice Wolin; Michele L. Basche

Publisher: Springer
Year: 2005
Tongue: English
Weight: 259 KB
Volume: 56
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-004-0968-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical and pharmacokinetic study of TN

Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors

✍ Hai T. Tran; George R. Blumenschein; Charles Lu; Christina A. Meyers; Vali Papad 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 198 KB

A phase I dose escalation and pharmacoki

A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors

✍ E. Gabriela Chiorean; Srikar Malireddy; Anne E. Younger; David R. Jones; Mary-Ja 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 233 KB

A Phase I study to assess the safety, to

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

✍ J. R. Infante; R. Kurzrock; J. Spratlin; H. A. Burris; S. G. Eckhardt; J. Li; K. 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 338 KB